Composition and methods for treatment of sexual dysfunction

Abstract

Compositions and methods are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, wherein pharmaceutically sufficient quantities of a linear or cyclic peptide with a carboxyl terminus —OH group or pharmaceutically acceptable salt thereof and a core His-Phe-Arg-Trp (SEQ ID NO:1) or His-D-Phe-Arg-Trp sequence are administered. Methods of administration include injection, oral, nasal and mucosal administration.

1 . A method for stimulating sexual response in a mammal, comprising administering a pharmaceutically sufficient amount of a composition comprising a peptide with a carboxyl terminus —OH group or pharmaceutically acceptable salt thereof and a core His-Phe-Arg-Trp (SEQ ID NO:1) or His-D-Phe-Arg-Trp sequence.  
     
     
         2 . The method of  claim 1 , wherein the peptide is a linear peptide.  
     
     
         3 . The method of  claim 1 , wherein the peptide is a cyclic peptide.  
     
     
         4 . The method of  claim 3 , wherein the peptide is cyclicized through a covalent bond comprising two reactive amino acid side chains.  
     
     
         5 . The method of  claim 1 , wherein the mammal is a male.  
     
     
         6 . The method of  claim 1 , wherein the mammal is a female.  
     
     
         7 . The method of  claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.  
     
     
         8 . The method of  claim 1 , wherein administering comprises administering by a method of administration selected from the group consisting of administration by injection, administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.  
     
     
         9 . The method of  claim 1 , wherein administering comprises nasal administration of a metered amount of a formulation comprising an aqueous buffer.  
     
     
         10 . The method of  claim 9 , wherein the aqueous buffer is a member selected from the group consisting of saline and citrate buffer.  
     
     
         11 . A method for stimulating sexual response in a mammal, comprising administering a pharmaceutically sufficient amount of a composition comprising a linear peptide with a carboxyl terminus —OH group or pharmaceutically acceptable salt thereof and including the sequence His-Phe-Arg-Trp (SEQ ID NO:1) or His-D-Phe-Arg-Trp.  
     
     
         12 . The method of  claim 11 , wherein the mammal is a male.  
     
     
         13 . The method of  claim 11 , wherein the mammal is a female.  
     
     
         14 . The method of  claim 11 , wherein the composition further comprises a pharmaceutically acceptable carrier.  
     
     
         15 . The method of  claim 11 , wherein administering comprises administering by a method of administration selected from the group consisting of administration by injection, administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.  
     
     
         16 . The method of  claim 11 , wherein administering comprises nasal administration of a metered amount of a formulation comprising an aqueous buffer.  
     
     
         17 . The method of  claim 16 , wherein the aqueous buffer is a member selected from the group consisting of saline and citrate buffer.  
     
     
         18 . A method for stimulating sexual response in a mammal, comprising administering a pharmaceutically sufficient amount of a composition comprising a cyclic peptide with a carboxyl terminus —OH group or pharmaceutically acceptable salt thereof and including the sequence His-Phe-Arg-Trp (SEQ ID NO:1) or His-D-Phe-Arg-Trp sequence.  
     
     
         19 . The method of  claim 18 , wherein the cyclic peptide is cyclicized through a covalent bond comprising two reactive amino acid side chains.  
     
     
         20 . The method of  claim 18 , wherein the mammal is a male.  
     
     
         21 . The method of  claim 18 , wherein the mammal is a female.  
     
     
         22 . The method of  claim 18 , wherein the composition further comprises a pharmaceutically acceptable carrier.  
     
     
         23 . The method of  claim 18 , wherein administering comprises administering by a method of administration selected from the group consisting of administration by injection, administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.  
     
     
         24 . The method of  claim 18 , wherein administering comprises nasal administration of a metered amount of a formulation comprising an aqueous buffer.  
     
     
         25 . The method of  claim 24 , wherein the aqueous buffer is a member selected from the group consisting of saline and citrate buffer.